Motor analysis predicts progression in HIV-associated brain disease.
One hundred HIV-positive individuals without clinically evident central nervous system (CNS) deficits entered this follow-up study and were examined clinically and with a well-defined motor test battery every 3 months over 2 years or until they decreased. They underwent magnetic resonance tomography once a year. None received any form of therapy at onset of the study. Three groups were analyzed: (A) patients without electrophysiologically detectable motor impairment (n = 23), (B) patients with electrophysiologically detectable motor impairment but no virostatic medication (n = 33), and (C) patients with motor deficits undergoing AZT treatment (n = 44) after study onset. Group A patients, although slightly deteriorating over time, had the best clinical and electrophysiological outcome compared to the other groups, whereas group B patients deteriorated markedly in both clinical and electrophysiological tests, even though the majority did not develop cerebral complications during the observation period. Those group C patients belonging to early CDC stages (II and III) improved electrophysiologically under AZT therapy, while 76% of the patients in more advanced stages (CDC IVA-D) died of cerebral AIDS manifestations. Four patients of this group, being alive at the end of the study, were completely demented. It is suggested that early detectable motor impairment predicts future cerebral involvement in AIDS. Late onset of virostatic treatment did not influence the clinical outcome.
Arendt
G
G
Department of Neurology, Heinrich Heine University, Dusseldorf, Germany.
Hefter
H
H
Hilperath
F
F
von Giesen
H J
HJ
Strohmeyer
G
G
Freund
H J
HJ
D015526:AIDS Dementia Complex / Q000503:physiopathology*; D000328:Adult; D004594:Electrophysiology / Q000379:methods; D005260:Female; D005500:Follow-Up Studies; D006679:HIV Seropositivity / Q000188:drug therapy / Q000503:physiopathology*; D006801:Humans; D008279:Magnetic Resonance Imaging; D008297:Male; D009043:Motor Activity; D009460:Neurologic Examination; D011237:Predictive Value of Tests; D011379:Prognosis; D013997:Time Factors; D014202:Tremor; D015215:Zidovudine / Q000627:therapeutic use
D015215:Zidovudine